#USA #New York #Class Action #Bronstein #Capricor

Investor Alert: Capricor Therapeutics Class Action Lawsuit

In a significant legal move, Bronstein, Gewirtz & Grossman LLC, a well-respected law firm, has formally announced the initiation of a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and several of its executives. This legal action is generated by substantial financial losses experienced by investors, specifically those who acquired Capricor securities between October 9, 2024, and July 10, 2025. Individuals who believe they have been affected by these losses are urged to join the lawsuit by visiting the firm’s official website at bgandg.com/CAPR.

Why is the Lawsuit Being Filed?

The class action lawsuit targets Capricor Therapeutics for alleged breaches of federal securities laws. According to the complaint, the defendants made materially false and misleading statements and failed to disclose critical information regarding the company’s Phase 2 HOPE-2 trial of deramiocel, a treatment Capricor was developing. Specifically, the allegations suggest that:

1. Inadequate Safety and Efficacy Data: The safety and efficacy data gathered over four years was reportedly insufficient to support the approval of the treatment.
2. Overly Optimistic Public Statements: Statements made by the company concerning their likelihood of gaining regulatory approval were viewed as overly optimistic and lacking solid foundation.
3. Misleading Representations: The public representations regarding the business operations and future prospects of Capricor were found to be materially false and misleading, thereby affecting the investors’ decisions.

What Should Investors Do?

Investors who purchased or acquired Capricor securities during the specified class period can act by contacting Bronstein, Gewirtz & Grossman to explore their options. The firm emphasizes that potential plaintiffs do not need to serve as lead plaintiffs to benefit from the lawsuit outcome.

The deadline for investors to submit their request to be named as lead plaintiff is September 15, 2025. Interested individuals can access a copy of the complaint via the firm’s website for more comprehensive information.

No Upfront Costs Involved

Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, ensuring that investors do not incur any upfront costs. This means that if the firm succeeds in recovering funds for investors, they will receive reimbursement for relevant expenses and fees, typically a percentage of what is recovered.

Why Choose Bronstein, Gewirtz & Grossman?

With a strong reputation for representing investors in class actions and shareholder derivative suits, Bronstein, Gewirtz & Grossman has successfully recovered hundreds of millions for investors nationwide. Their commitment to providing legal representation to those affected by securities fraud has made them a reputable choice in the legal community.

Stay Informed

Investors are encouraged to follow Bronstein, Gewirtz & Grossman on social media platforms such as LinkedIn, Twitter, Facebook, and Instagram for ongoing updates regarding the case and other pertinent news.

For further inquiries or to discuss potential participation in the lawsuit, investors can reach out to Peretz Bronstein or his Client Relations Manager, Nathan Miller, at (332) 239-2660 or via email.

As the legal proceedings unfold, affected investors can take proactive steps to recover their losses and seek justice against any misleading practices related to Capricor Therapeutics.